Patient Information Leaflet
Entresto24mg/26mgfilm-coated tablets
Entresto49mg/51mgfilm-coated tablets
Entresto97mg/103mgfilm-coated tablets
sacubitrilo/valsartán
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
-This medicine has been prescribed for you only. Do not give it to others even if they have similar symptoms to you, as it may harm them.
1.What Entresto is and what it is used for
2.What you need to know before you start taking Entresto
3.How to take Entresto
4.Possible side effects
5.Storage of Entresto
6.Contents of the pack and additional information
Entresto is a heart medication that contains a neprilisin inhibitor and an angiotensin receptor inhibitor. It provides two active principles, sacubitrilo and valsartán.
Entresto is used for the treatment of a type of heart failure in adults, children, and adolescents (from one year of age).
This type of heart failure occurs when the heart is weak and cannot pump enough blood to the lungs and the rest of the body. The most common symptoms of heart failure aredifficulty breathing, fatigue, tiredness, and swelling of the ankles.
Do not take Entresto
If you are in one of these cases, do not take Entresto and talk to your doctor.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take or while taking Entresto:
If you are in one of these cases, talk to your doctor, pharmacist, or nurse before taking Entresto.
Your doctor may check your potassium and sodium levels in your blood at regular intervals during treatment with Entresto. Additionally, your doctor may check your blood pressure at the start of treatment and when increasing doses.
Children and adolescents
Do not give this medication to children under 1year as it has not been studied in this age group. For children 1 year and older with a body weight below40kg, this medication will be administered in granules (instead of tablets).
Taking Entresto with other medications
Inform your doctor, pharmacist, or nurse if you are taking, have taken recently, or may need to take any other medication. It may be necessary to change the dose, take other precautions, or even stop taking one of the medications. This is especially important for the following medications:
If you are in one of these cases, talk to your doctor or pharmacist before taking Entresto.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
Inform your doctor if you think you are (or may become) pregnant. Your doctor will usually advise you to stop taking this medication before becoming pregnant or as soon as you know you are pregnant, and will advise you to take another medication instead of Entresto.
This medication is not recommended in early pregnancy, and should not be taken when more than 3months pregnant, as it could cause serious harm to your baby if used after the third month of pregnancy.
Breastfeeding
Entresto is not recommended for mothers who are breastfeeding. Inform your doctor if you are breastfeeding or planning to start breastfeeding.
Driving and operating machinery
Before driving a vehicle, using tools, or operating machinery, or engaging in other activities that require concentration, make sure you know how Entresto affects you. If you feel dizzy or very tired while taking this medication, do not drive a vehicle, ride a bike, or use machinery.
Entresto contains sodium
This medication contains less than 1mmol of sodium (23mg) per dose of 97mg/103mg; this is, essentially “sodium-free”.
Adults
Normally, you will start taking one tablet of 24mg/26mg or 49mg/51mg twice a day (one tablet in the morning and one tablet at night). Your doctor will decide your exact initial dose based on the medication you have been taking previously and your blood pressure. Your doctor will then adjust the dose every2-4weeksdepending on how you respond to the treatment until finding the best dose for you.
The recommended target dose is 97mg/103mg twice a day (one tablet in the morning and one tablet at night).
Children and adolescents (one year and older)
Your doctor (or your child's doctor) will decide the initial dose based on your child's weight and other factors, including medications taken previously. The doctor will adjust the dose every2-4weeksuntil finding the best dose.
Entresto should be taken twice a day (one tablet in the morning and one tablet at night)
Entresto film-coated tablets should not be used in children weighing less than 40kg. For these patients, Entresto granules are available.
Patients taking Entresto may develop low blood pressure (dizziness, feeling of faintness), high potassium levels in the blood (which may be detected when your doctor performs a blood test) or decreased kidney function. If this occurs, your doctor may reduce the dose of one of the other medications you are taking, temporarily reduce the Entresto dose, or stop Entresto treatment completely.
Swallow the tablets with a glass of water. You can take Entresto with or without food. Do not recommend dividing or crushing the tablets.
If you take more Entresto than you should
If you accidentally take too many Entresto tablets, or if someone has taken your tablets, contact your doctor immediately. If you experience severe dizziness and/or fatigue, inform your doctor as soon as possible and lie down.
If you forget to take Entresto
It is recommended to take your medication at the same time every day. However, if you have forgotten to take Entresto, simply take the next dose at the scheduled time.Do not take a double dose to compensate for the missed doses.
If you stop taking Entresto
If you stop taking Entresto, your condition may worsen. Do not stop taking your medication unless your doctor tells you to.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Some side effects can be serious
Other possible side effects:
If any of the side effects listed below become severe, report them to your doctor or pharmacist.
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Rare(may affect up to 1 in 100 people)
Very rare(may affect up to 1 in 10,000 people)
Very rare(may affect up to 1 in 10,000 people)
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and in the blister pack after CAD/EXP. The expiration date is the last day of the month indicated.
This medication does not require any special storage temperature.
Store in the original packaging to protect it from moisture.
Do not use this medication if you observe that the packaging is damaged or shows signs of handling.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. This will help protect the environment.
Composition of Entresto
Appearance of the product and contents of the pack
Entresto 24 mg/26 mg film-coated tablets are white to pale violet, oval-shaped tablets with the inscription “NVR” on one side and “LZ” on the other. The approximate dimensions of the tablets are 13.1 mm x 5.2 mm.
Entresto 49 mg/51 mg film-coated tablets are pale yellow, oval-shaped tablets with the inscription “NVR” on one side and “L1” on the other. The approximate dimensions of the tablets are 13.1 mm x 5.2 mm.
Entresto 97 mg/103 mg film-coated tablets are pale pink, oval-shaped tablets with the inscription “NVR” on one side and “L11” on the other. The approximate dimensions of the tablets are 15.1 mm x 6.0 mm.
The tablets are presented in packs containing 14, 20, 28, 56, 168, or 196 tablets and in multiple packs which include 7 packs, each containing 28 tablets. The 49 mg/51 mg and 97 mg/103 mg tablets are also presented in multiple packs which include 3 packs, each containing 56 tablets.
Only some pack sizes may be marketed.
Marketing authorisation holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Responsible for manufacturing
Novartis Pharmaceutical Manufacturing LLC
Verovška Ulica 57
1000 Ljubljana
Slovenia
Novartis Farma S.p.A
Via Provinciale Schito 131
80058 Torre Annunziata (NA)
Italy
Novartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany
LEK farmacevtska družba d.d., Poslovna enota PROIZVODNJA LENDAVA
Trimlini 2D
Lendava 9220
Slovenia
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nürnberg
Germany
For further information about this medicinal product, please consult the representative of the marketing authorisation holder in your country:
België/Belgique/Belgien Novartis Pharma N.V. Tel: +32 2 246 16 11 | Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16 50 |
Luxembourg/Luxemburg Novartis Pharma N.V. Tel: +32 2 246 16 11 | |
Ceská republika Novartis s.r.o. Tel: +420 225 775 111 | Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00 |
Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +356 2122 2872 |
Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 | Nederland Novartis Pharma B.V. Tel: +31 88 04 52 111 |
Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 810 | Norge Novartis Norge AS Tlf: +47 23 05 20 00 |
Ελλ?δα Novartis (Hellas) A.E.B.E. Tel: +30 210 281 17 12 | Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 |
España Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888 |
France Novartis Pharma S.A.S. Tel: +33 1 55 47 66 00 | Portugal Novartis Farma‑Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 | România Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Ísland Vistor hf. Tel: +354 535 7000 | Slovenská republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5439 |
Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Suomi/Finland Novartis Finland Oy Tel: +358 (0)10 6133 200 |
Κ?προς Novartis Pharma Services Inc. Tel: +357 22 690 690 | Sverige Novartis Sverige AB Tel: +46 8 732 32 00 |
Latvija SIA Novartis Baltics Tel: +371 67 887 070 |
Last update of the summary of product characteristics:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.